How did Edwards Lifesciences' revenue and expenses trend in Q4 2024?

Edwards Lifesciences' revenue for Q4 2024 was $1.39 billion, reflecting a strong performance, particularly in their Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. However, no data was provided regarding expenses for Q4 2024.

1. **Revenue Analysis**: The company's revenue trend in Q4 2024 was positive, with a reported total revenue of $1.39 billion. This is a notable figure, indicating the company's continued success in the market. The growth in revenue can be attributed to strong sales in the TAVR and TMTT segments, which grew by 6% and 73%, respectively.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|EW|EW.N|Edwards Lifesciences|2024 Q1|9.495752260893395|1.5982E9|169|
|EW|EW.N|Edwards Lifesciences|2024 Q2|6.97800077190274|1.3859E9|169|
|EW|EW.N|Edwards Lifesciences|2024 Q3|8.92713527424803|1.3544E9|169|
|EW|EW.N|Edwards Lifesciences|2024 Q4|9.428300694883134|1.3858E9|169|

2. **Expense Analysis**: There was no available data on the company's expenses for Q4 2024. However, in the third quarter, the company's selling, general, and administrative expenses were $421 million, which is a significant figure. It is important for the company to manage these expenses effectively to maintain profitability.

Edwards Lifesciences' focus on strategic divestitures and investments, as evidenced by the sale of its Critical Care business and the investment in platforms for structural heart, is likely to have had an impact on both revenue and expenses. The company's gross margin is expected to be in-line with the high end of its 76% to 78% full-year guidance range, indicating a strong profitability outlook.